A tech giant thrived, a novel product took off, and an under-siege behemoth somehow survived. Read More
Related Articles
Why the end of Katerra doesn’t mean the end of construction tech investing
Posted on Author admin
Katerra’s failure hasn’t quite set a pallor through the industry Read More
AstraZeneca-Oxford COVID vaccine could get U.K. approval as soon as this week
Posted on Author admin
The U.K. is poised to approve the COVID-19 vaccine produced by AstraZeneca Plc and the University of Oxford, giving the country another powerful tool to fight the pandemic as concern mounts over rising infections. Britain’s drug regulator could clear the shot for use as early as this week, according to a person familiar with the […]
There are smarter ways to think about board diversity, and the pressure is on to figure them out
Posted on Author admin
Speaking out against questionable management can pose a risk for tech workers in the minority—but that’s about to change by an act of solidarity. Read More